Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 20/20 | 0.79 |
| ▸ | PIM2 | Q9P1W9 | 12/20 | 0.79 |
| ▸ | FLT3 | P36888 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16210821 | 0.88 | PIM1 (1.00) | PIM1PIM2FLT3 | |
| SCHEMBL102496 | 0.88 | PIM1 (1.00) | PIM1PIM2FLT3 | |
| SCHEMBL19987110 | 0.88 | PIM1 (0.81) | PIM1PIM2FLT3 | |
| SCHEMBL102727 | 0.82 | PIM1 (1.00) | PIM1PIM2FLT3 | |
| SCHEMBL135092 | 0.82 | PIM1 (1.00) | PIM1PIM2FLT3 | |
| SCHEMBL102862 | 0.82 | PIM1 (1.00) | PIM1PIM2FLT3 | |
| SCHEMBL14639094 | 0.81 | PIM1 (1.00) | PIM1PIM2FLT3 | |
| SCHEMBL102495 | 0.80 | PIM1 (1.00) | PIM1PIM2FLT3 | |
| SCHEMBL178295 | 0.80 | PIM1 (1.00) | PIM1PIM2FLT3 | |
| SCHEMBL102967 | 0.79 | PIM1 (1.00) | PIM1PIM2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885FLT3 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.